Zolmitriptan
| Clinical data | |
|---|---|
| Trade names | Zomig, others |
| Other names | BW-311C90; BW311C90; 311C90; BW-311-C-90; ML-004; ML004; [(4S)-2-Oxo-1,3-oxazolidin-4-yl]methyl-N,N-dimethyltryptamine |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a601129 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth, intranasal |
| Drug class | Serotonin 5-HT1B and 5-HT1D receptor agonist; Antimigraine agent; Triptan |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | Oral: 40% |
| Protein binding | 25% |
| Metabolism | Liver (CYP1A2-mediated, to active metabolite; also MAO) |
| Metabolites | • N-Desmethylzolmitriptan • Zolmitriptan N-oxide • Indole acetic acid derivative |
| Elimination half-life | Zolmitriptan: 3 hours N-Desmethylzolmitriptan: 3.5 hours |
| Excretion | Urine: ~65% Feces: ~30% |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.158.186 |
| Chemical and physical data | |
| Formula | C16H21N3O2 |
| Molar mass | 287.363 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Zolmitriptan, sold under the brand name Zomig among others, is a serotonergic medication which is used in the acute treatment of migraine attacks with or without aura and cluster headaches. It is taken by mouth as a swallowed or disintegrating tablet or as a nasal spray.
Side effects include tightness in the neck or throat, jaw pain, dizziness, paresthesia, asthenia, somnolence, warm/cold sensations, nausea, chest pressure, and dry mouth. The drug acts as a selective serotonin 5-HT1B and 5-HT1D receptor agonist. Structurally, it is a triptan and a tryptamine derivative.
It was patented in 1990 and was approved for medical use in 1997.